TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02230111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction plus CDR
Description: Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction without CDR
Description: Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
Study: NCT04164524

Intervention type: DRUG
Intervention: Gentamycin
Description: Gentamycin 160 mg spray applied over the mesh
Study: NCT00643708

Intervention type: PROCEDURE
Intervention: ovarian interstitial laser treatment
Description: Different dose of laser: group A, one point per ovary.

Intervention type: PROCEDURE
Intervention: ovarian interstitial laser treatment
Description: Different dose of laser: group B, two points per ovary.

Intervention type: PROCEDURE
Intervention: ovarian interstitial laser treatment
Description: Different dose of laser: group c, three points per ovary.
Study: NCT04381481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Drink: Nutrition claim on fruit drinks
Description: Fruit drink contains a nutrition claim (task 1)
Study: NCT00643708

Intervention type: PROCEDURE
Intervention: ovarian interstitial laser treatment
Description: Different dose of laser: group D, four-five points per ovary.
Study: NCT02219906

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1000mg tid

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000mg tid placebo
Study: NCT04375826

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural patient controlled analgesia
Description: The device is connected to the epidural catheter prior to surgery and drug administration is started during surgery. The continuous infusion rate is 4 ml / hr. When the button is pressed, 2 ml is additionally administered and the lock time is 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Preperitoneal analgesia and IV-PCA
Description: During surgery, the preperitoneal analgesia catheters are inserted into the preperitoneal space and these catheters are connected to the pump with ropivacaine.
Study: NCT02410291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
Study: NCT02637544

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: classical acupuncture therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: classical acupuncture therapy
Study: NCT02430532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matched placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matched placebo capsule
Study: NCT03995810

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine, capsulle, 2 g/day, 8 weeks
Description: We will administer supplemental carnosine (2 grams per day) for 8 weeks
Study: NCT02997618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based exercise programme
Description: 20 week community (home or gym based) exercise programme

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual care consisting of advice.
Study: NCT02438800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LARC First Video
Description: LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
Study: NCT01899222

Intervention type: DEVICE
Intervention: Handheld fundus photography
Description: diagnostic imaging with two types of retina camera
Study: NCT04249141

Intervention type: OTHER
Intervention: Survey and concept mapping
Description: ICU providers who participoated in SCCM ICU Liberation Collaborative will be invited to participate in surveys and a concept mapping excercise
Study: NCT03408574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, oral mecamylamine, placebo
Description: Each participant randomly receives one active drug or placebo on each of three study days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch, oral mecamylamine, placebo
Description: Each participant randomly receives one active drug or placebo on each of three study days.
Study: NCT04150874

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumason®
Description: Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
Study: NCT02797405

Intervention type: RADIATION
Group type: OTHER
Intervention: Standard treatment
Description: Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
Study: NCT02576418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partosure TTD test
Description: PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
Study: NCT02962336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets
Description: Oral, crossover

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tribenzor Tablets of Daichi Sankyo Inc, USA
Description: Oral, crossover
Study: NCT00841282

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy for colorectal cancer screening

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy for colorectal cancer screening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water Infusion Colonoscopy
Description: water infusion in lieu of air insufflation for screening colonoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Air insufflation colonoscopy
Description: Conventional colonoscopy with air insufflation
Study: NCT00368719

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tacrolimus
Description: Participants will be followed for 10 years to study the effects of Tacrolimus.
Study: NCT01738555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amdoxovir 300 mg bid
Description: 2 x 150 mg capsules bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amdoxovir 500 mg bid
Description: 2 x 250 mg capsules bid
Study: NCT03607799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control group participants will be provided with PDFs, website links to encourage healthy eating, physical activity, and other lifestyle factors during pregnancy. They will also receive weekly text messages aimed at increasing walking.
Study: NCT02952053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MTrP Group
Description: Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TB Group
Description: Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions.
Study: NCT01760044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue oxygenation monitoring
Description: The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
Study: NCT04208867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: QI Collaborative
Description: Facilities that participated in a QI collaborative to improve PCC for MH services
Study: NCT03124108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elafibranor 80 mg
Description: Two coated tablets daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elafibranor 120 mg
Description: Two coated tablets daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two coated tablets daily for 12 weeks
Study: NCT02199145

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood and urine analysis
Description: creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
Study: NCT03369301

Intervention type: DRUG
Intervention: Gammanorm
Description: Gammanorm given per standard of care

Intervention type: DRUG
Intervention: Other Subcutaneous Immunoglobulins
Description: Other Subcutaneous Immunoglobulins given per standard of care
Study: NCT00817986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil, 20 mg
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil, 30 mg
Description: tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil, 40 mg
Description: tablets
Study: NCT03076619

Intervention type: OTHER
Intervention: clinical ophthalmoscopy
Description: To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
Study: NCT00528177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine and oxycodone
Description: At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning.
Study: NCT04381481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Drink: No nutrition claim
Description: Fruit drinks does not contain a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Drink: No nutrition claim
Description: Fruit drinks does not contain a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Drink: No nutrition claim
Description: Fruit drinks does not contain a nutrition claim (task 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Text warning
Description: The snack contains a text warning (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Text warning
Description: The snack contains a text warning (task 2)
Study: NCT03886727

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rubber Dam Set
Description: Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Cotton Roll
Description: Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
Study: NCT04381481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Text warning
Description: The snack contains a text warning (task 2)
Study: NCT01848964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical and instrumented measurements
Description: Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate.
Study: NCT03298178

Intervention type: PROCEDURE
Intervention: TAVR
Description: All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea

Intervention type: PROCEDURE
Intervention: SAVR
Description: All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
Study: NCT04381481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Graphic warning
Description: The snack contains a graphic warning (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Graphic warning
Description: The snack contains a graphic warning (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Graphic warning
Description: The snack contains a graphic warning (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental snack: Graphic warning
Description: The snack contains a graphic warning (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control snack: barcode label
Description: The snack contains a neutral barcode label (task 2)
Study: NCT00993603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 8-month group lifestyle programme
Description: Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
Study: NCT04415489

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Office hysteroscopy
Description: Use of hysteroscopy in the clinical setting to directly visualize the cavity. If pathology amenable to immediate treatment is visualize, removal will be attempted by hysteroscopic graspers.
Study: NCT02126111

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DEPIGOID phleum
Description: Subcutaneous Immunotherapy with modified extract of Phleum pollen.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DEPIGOID phleum
Description: Subcutaneous Immunotherapy with modified extract of Phleum pollen.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DEPIGOID Placebo
Description: Placebo for subcutaneous administration
Study: NCT04169568

Intervention type: PROCEDURE
Intervention: Manual cuff blood pressure
Description: Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
Study: NCT02568033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study: NCT03545724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neofitoroid®
Description: NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
Study: NCT03951194

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma (PRP) intra ovarian infusion
Description: Autologous PRP intra ovarian infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion
Description: Autologous PFP intra ovarian infusion
Study: NCT04368403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: 210 mg every 2 weeks (Q2W), subcutaneous (SC) injection
Study: NCT04381481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control snack: barcode label
Description: The snack contains a neutral barcode label (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control snack: barcode label
Description: The snack contains a neutral barcode label (task 2)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control snack: barcode label
Description: The snack contains a neutral barcode label (task 2)
Study: NCT01889472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy
Study: NCT04458558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Participants will receive mifepristone at a preferred address by mail rather than standard care at clinic visit.
Study: NCT01669031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice program
Description: Each practice session (simulated visual field test on computer) takes 3-15 minutes
Study: NCT00867854

Intervention type: OTHER
Intervention: Blood draw
Description: This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.

Intervention type: OTHER
Intervention: Blood draw
Description: This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.